RHOJ derived peptide promotes chemosensitivity by inhibiting glutamine metabolism in gastric cancer
Open Access
- 28 January 2026
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Abstract
Chemoresistance is a cause of chemotherapy failure in gastric cancer (GC) treatment. Recent studies have shown that the dysregulation of glutamine metaboliKeywords
All Related Versions
This publication has 53 references indexed in Scilit:
- GLUL stabilizes N-Cadherin by antagonizing β-Catenin to inhibit the progresses of gastric cancerActa Pharmaceutica Sinica B, 2023
- Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancerCancer Communications, 2023
- Rhoj Is a Novel Target for Progression and Invasion of Glioblastoma by Impairing Cytoskeleton DynamicsNeurotherapeutics, 2020
- Burden of Gastric CancerClinical Gastroenterology and Hepatology, 2019
- Haploinsufficiency of SIRT1 Enhances Glutamine Metabolism and Promotes Cancer DevelopmentCurrent Biology, 2017
- Hypoxia promotes mitochondrial glutamine metabolism through HIF1α-GDH pathway in human lung cancer cellsBiochemical and Biophysical Research Communications, 2017
- Peptide-based cancer therapy: Opportunity and challengeCancer Letters, 2014
- Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular DisruptionCancer Cell, 2014
- Altered Glutamine Metabolism and Therapeutic Opportunities for Lung CancerClinical Lung Cancer, 2014
- GROMACS: Fast, flexible, and freeJournal of Computational Chemistry, 2005